1e
19
1
49
2
2
18
1b
1d
18
35
6e
1d
2 29
1d
25
Perry B. Molinoff, M.D.
78
6e
Emeritus Professor of Systems Pharmacology and Translational Therapeutics
7
8a
Department: Systems Pharmacology and Translational Therapeutics
4
1
b
1d
46
Contact information
48
4
3
3
1d
48
Department of Pharmacology
41 204 Anatomy-Chemistry Building
Philadelphia, PA 19104
26
41 204 Anatomy-Chemistry Building
Philadelphia, PA 19104
30
Office: (215) 898-2832
34 Fax: (215) 898-2718
24
91
34 Fax: (215) 898-2718
24
Email:
molinoff@pobox.upenn.edu
12
molinoff@pobox.upenn.edu
18
Publications
23 a
3
2
29
23 a
Links
9a Search PubMed for articles
d
4
b
1f
9a Search PubMed for articles
d
13
Education:
21 9 B.S. c
34 Harvard College, Boston, MA, 1962.
21 9 M.D. c
37 Harvard University, Boston, MA, 1967.
c
3
3
3
3
8a
Permanent link21 9 B.S. c
34 Harvard College, Boston, MA, 1962.
21 9 M.D. c
37 Harvard University, Boston, MA, 1967.
c
2 29
21
1e
1d
24
5e
26 29
27
Description of Research Expertise
217 Dr. Molinoff is an expert on the structure and function of cell membrane receptors involved in signal transduction. His early research focused on the receptor for the neurotransmitter acetylcholine, but he has published extensively on other important receptor molecules that respond to amino acids or to biogenic amines such as dopamine. Much of this research has had significant clinical relevance for understanding and treating diseases ranging from heart failure to depression, schizophrenia and Parkinson's disease.26 29
23
19a Diamond LE, Earle DC, Rosen RC, Willett MS, Molinoff PB: Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. Intl J Impotence Res 16: 51-59, 2004.
15f Nakai S, Hirose T, Uwahodo Y, Imaoka T, Okazaki H, Miwa T, Nakai M, Yamada S, Dunn B, Burris KD, Molinoff PB, Tottori K, Altar CA, Kikuchi T: Diminished catalepsy and dopamine metabolism distinguish aripiprazole from haloperidol or risperidone. Eur J Pharmacol 472: 89-97, 2003.
f1 Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY: PT-141: A melanocortin agonist for the treatment of sexual dysfunction. Ann New York Acad Sci 994: 96-102, 2003.
12a Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, Yocca FD, Molinoff PB: Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 302: 381-389, 2002.
d7 Molinoff PB: Common to both academia and industry: The challenge of discovery. An interview with Perry Molinoff. Mol Intervent 1: 78-83, 2001.
223 Gribkoff VK, Starrett JE Jr, Dworetzky SI, Hewawasam P, Boissard CG, Cook DA, Frantz SW, Heman K, Hibbard JR, Huston K, Johnson G, Krishnan BS, Kinney GG, Lombardo LA, Meanwell NA, Molinoff PB, Myers RA, Moon SL, Ortiz A, Pajor L, Pieschl RL., Post-Munson DJ, Signor LJ, Srinivas N, Taber MT, Thalody G, Trojnacki JT, Wiener H, Yeleswaram K, Yeola SW: Targeting acute ischemic stroke with a calcium-sensitive opener of maxi-K potassium channels. Nature Med 7: 471-477, 2001.
10d Wohlpart KL and Molinoff PB: Characterization of 5-HT- and ionomycin-stimulated changes in levels of intracellular calcium and PI hydrolysis in P11 cells. Ann New York Acad Sci 861: 240-241, 1998.
e1 Burris KD, Fausing SM, Molinoff PB: Regulation of D2 and D3 receptors in transfected cells by agonists and antagonists. Adv Pharmacol 42: 443-446, 1998.
129 Cowen DS, Molinoff PB, Manning DR: 5-hydroxytryptamine1A receptor-mediated increases in receptor expression and activation of nuclear factor-kappaB in transfected Chinese hamster ovary cells. Mol Pharmacol 52: 221-226, 1997.
2c
7
1d
1f
Selected Publications
189 Rosen RC, Diamond LE, Earle DC, Shadiack AM, Molinoff PB: Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra. Intl J Impotence Res 16: 135-142, 2004.19a Diamond LE, Earle DC, Rosen RC, Willett MS, Molinoff PB: Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. Intl J Impotence Res 16: 51-59, 2004.
15f Nakai S, Hirose T, Uwahodo Y, Imaoka T, Okazaki H, Miwa T, Nakai M, Yamada S, Dunn B, Burris KD, Molinoff PB, Tottori K, Altar CA, Kikuchi T: Diminished catalepsy and dopamine metabolism distinguish aripiprazole from haloperidol or risperidone. Eur J Pharmacol 472: 89-97, 2003.
f1 Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY: PT-141: A melanocortin agonist for the treatment of sexual dysfunction. Ann New York Acad Sci 994: 96-102, 2003.
12a Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, Yocca FD, Molinoff PB: Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 302: 381-389, 2002.
d7 Molinoff PB: Common to both academia and industry: The challenge of discovery. An interview with Perry Molinoff. Mol Intervent 1: 78-83, 2001.
223 Gribkoff VK, Starrett JE Jr, Dworetzky SI, Hewawasam P, Boissard CG, Cook DA, Frantz SW, Heman K, Hibbard JR, Huston K, Johnson G, Krishnan BS, Kinney GG, Lombardo LA, Meanwell NA, Molinoff PB, Myers RA, Moon SL, Ortiz A, Pajor L, Pieschl RL., Post-Munson DJ, Signor LJ, Srinivas N, Taber MT, Thalody G, Trojnacki JT, Wiener H, Yeleswaram K, Yeola SW: Targeting acute ischemic stroke with a calcium-sensitive opener of maxi-K potassium channels. Nature Med 7: 471-477, 2001.
10d Wohlpart KL and Molinoff PB: Characterization of 5-HT- and ionomycin-stimulated changes in levels of intracellular calcium and PI hydrolysis in P11 cells. Ann New York Acad Sci 861: 240-241, 1998.
e1 Burris KD, Fausing SM, Molinoff PB: Regulation of D2 and D3 receptors in transfected cells by agonists and antagonists. Adv Pharmacol 42: 443-446, 1998.
129 Cowen DS, Molinoff PB, Manning DR: 5-hydroxytryptamine1A receptor-mediated increases in receptor expression and activation of nuclear factor-kappaB in transfected Chinese hamster ovary cells. Mol Pharmacol 52: 221-226, 1997.
2c